122 related articles for article (PubMed ID: 11772452)
1. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs.
Ríhová B; Strohalm J; Kubácková K; Jelínková M; Hovorka O; Kovár M; Plocová D; Sírová M; St'astný M; Rozprimová L; Ulbrich K
J Control Release; 2002 Jan; 78(1-3):97-114. PubMed ID: 11772452
[TBL] [Abstract][Full Text] [Related]
2. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
3. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators.
Ríhová B; Jelínková M; Strohalm J; Subr V; Plocová D; Hovorka O; Novák M; Plundrová D; Germano Y; Ulbrich K
J Control Release; 2000 Feb; 64(1-3):241-61. PubMed ID: 10640661
[TBL] [Abstract][Full Text] [Related]
4. Induction of systemic antitumour resistance with targeted polymers.
Rihova B; Strohalm J; Kovar M; Mrkvan T; Subr V; Hovorka O; Sirova M; Rozprimova L; Kubackova K; Ulbrich K
Scand J Immunol; 2005 Jul; 62 Suppl 1():100-5. PubMed ID: 15953192
[TBL] [Abstract][Full Text] [Related]
5. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data.
Ríhová B; Strohalm J; Prausová J; Kubácková K; Jelínková M; Rozprimová L; Sírová M; Plocová D; Etrych T; Subr V; Mrkvan T; Kovár M; Ulbrich K
J Control Release; 2003 Aug; 91(1-2):1-16. PubMed ID: 12932633
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.
Ríhová B; Etrych T; Pechar M; Jelínková M; Stastný M; Hovorka O; Kovár M; Ulbrich K
J Control Release; 2001 Jul; 74(1-3):225-32. PubMed ID: 11489498
[TBL] [Abstract][Full Text] [Related]
7. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
[TBL] [Abstract][Full Text] [Related]
8. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo effect of HPMA copolymer-bound doxorubicin targeted to transferrin receptor of B-cell lymphoma 38C13.
Kovár M; Strohalm J; Ulbrich K; Ríhová B
J Drug Target; 2002 Feb; 10(1):23-30. PubMed ID: 11996083
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
Ríhová B; Jelínková M; Strohalm J; St'astný M; Hovorka O; Plocová D; Kovár M; Dráberová L; Ulbrich K
Bioconjug Chem; 2000; 11(5):664-73. PubMed ID: 10995209
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
[TBL] [Abstract][Full Text] [Related]
12. Differences in the intracellular fate of free and polymer-bound doxorubicin.
Hovorka O; St'astný M; Etrych T; Subr V; Strohalm J; Ulbrich K; Ríhová B
J Control Release; 2002 Apr; 80(1-3):101-17. PubMed ID: 11943391
[TBL] [Abstract][Full Text] [Related]
13. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage.
Nakamura H; Etrych T; Chytil P; Ohkubo M; Fang J; Ulbrich K; Maeda H
J Control Release; 2014 Jan; 174():81-7. PubMed ID: 24269967
[TBL] [Abstract][Full Text] [Related]
14. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
15. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
16. Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs.
Jelínková M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Pharm Res; 2003 Oct; 20(10):1558-64. PubMed ID: 14620507
[TBL] [Abstract][Full Text] [Related]
17. Cooperativity between free and N-(2-hydroxypropyl) methacrylamide copolymer bound adriamycin and meso-chlorin e6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro.
Lu JM; Peterson CM; Guo-Shiah J; Gu ZW; Peterson CA; Straight RC; Kopecek J
Int J Oncol; 1999 Jul; 15(1):5-16. PubMed ID: 10375588
[TBL] [Abstract][Full Text] [Related]
18. Polymer therapeutics with a coiled coil motif targeted against murine bcl1 leukemia.
Pola R; Laga R; Ulbrich K; Sieglová I; Král V; Fábry M; Kabešová M; Kovář M; Pechar M
Biomacromolecules; 2013 Mar; 14(3):881-9. PubMed ID: 23373696
[TBL] [Abstract][Full Text] [Related]
19. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier.
St'astný M; Strohalm J; Plocová D; Ulbrich K; Ríhová B
Eur J Cancer; 1999 Mar; 35(3):459-66. PubMed ID: 10448300
[TBL] [Abstract][Full Text] [Related]
20. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
